NASDAQ:ABMD - ABIOMED Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $384.88 +2.90 (+0.76 %) (As of 09/24/2018 06:27 AM ET)Previous Close$381.98Today's Range$380.97 - $386.7252-Week Range$158.71 - $450.93Volume1.57 million shsAverage Volume527,937 shsMarket Capitalization$17.27 billionP/E Ratio157.09Dividend YieldN/ABeta-0.08 Company ProfileDiscussionAnalyst RatingsChartEarnings HistoryFinancialsInsider TradesHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email ABIOMED, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides continuum of care to heart failure patients. The company offers Impella 2.5 catheter, a percutaneous micro heart pump with integrated motor and sensors for use in interventional cardiology; and Impella CP, a device used by interventional cardiologists to support patients in the cath lab and cardiac surgeons in the heart surgery suite. It also provides Impella 5.0 and Impella LD, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; and Impella RP, a percutaneous catheter-based axial flow pump. In addition, the company is involved in the development of Impella 5.5 and Impella BTR that are percutaneous micro heart pumps with integrated motors and sensors; and Impella ECP pump, a device for blood flow of greater than three liters per minute. It sells its products through direct sales and clinical support personnel in the United States, Canada, Europe, and Japan. The company was founded in 1981 and is headquartered in Danvers, Massachusetts. Receive ABMD News and Ratings via Email Sign-up to receive the latest news and ratings for ABMD and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Surgical & medical instruments Sub-IndustryHealth Care Equipment SectorMedical SymbolNASDAQ:ABMD CUSIP00365410 Webwww.abiomed.com Phone978-646-1400 Debt Debt-to-Equity RatioN/A Current Ratio6.49 Quick Ratio5.76 Price-To-Earnings Trailing P/E Ratio157.09 Forward P/E Ratio111.24 P/E Growth4.11 Sales & Book Value Annual Sales$593.75 million Price / Sales29.09 Cash Flow$2.7817 per share Price / Cash138.36 Book Value$15.57 per share Price / Book24.72 Profitability EPS (Most Recent Fiscal Year)$2.45 Net Income$112.17 million Net Margins25.71% Return on Equity18.91% Return on Assets16.64% Miscellaneous Employees1,143 Outstanding Shares44,880,000Market Cap$17.27 billion ABIOMED (NASDAQ:ABMD) Frequently Asked Questions What is ABIOMED's stock symbol? ABIOMED trades on the NASDAQ under the ticker symbol "ABMD." How were ABIOMED's earnings last quarter? ABIOMED, Inc. (NASDAQ:ABMD) announced its earnings results on Thursday, July, 26th. The medical equipment provider reported $1.95 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of $0.80 by $1.15. The medical equipment provider had revenue of $180.01 million for the quarter, compared to analyst estimates of $173.87 million. ABIOMED had a return on equity of 18.91% and a net margin of 25.71%. ABIOMED's quarterly revenue was up 35.9% on a year-over-year basis. During the same period in the prior year, the company posted $0.82 EPS. View ABIOMED's Earnings History. When is ABIOMED's next earnings date? ABIOMED is scheduled to release their next quarterly earnings announcement on Thursday, October, 25th 2018. View Earnings Estimates for ABIOMED. What price target have analysts set for ABMD? 8 equities research analysts have issued 12-month price targets for ABIOMED's shares. Their predictions range from $280.00 to $480.00. On average, they anticipate ABIOMED's stock price to reach $363.1429 in the next twelve months. This suggests that the stock has a possible downside of 5.6%. View Analyst Price Targets for ABIOMED. What is the consensus analysts' recommendation for ABIOMED? 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ABIOMED in the last year. There are currently 2 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for ABIOMED. Who are some of ABIOMED's key competitors? Some companies that are related to ABIOMED include Stryker (SYK), Boston Scientific (BSX), Baxter International (BAX), FRESENIUS SE &/S (FSNUY), ResMed (RMD), Teleflex (TFX), DexCom (DXCM), Hill-Rom (HRC), Insulet (PODD), Haemonetics (HAE), ICU Medical (ICUI), Integra Lifesciences (IART), Globus Medical (GMED), Penumbra (PEN) and Novocure (NVCR). Who are ABIOMED's key executives? ABIOMED's management team includes the folowing people: Mr. Michael R. Minogue, Chairman, CEO & Pres (Age 51)Dr. David M. Weber, Chief Operating Officer (Age 57)Mr. Michael G. Howley, VP & GM of Global Sales (Age 54)Mr. William J. Bolt, Sr. VP of Global Quality, Regulatory & Clinical Operations (Age 66)Mr. Ian McLeod, VP & Corp. Controller Who are ABIOMED's major shareholders? ABIOMED's stock is owned by many different of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (6.30%), Baillie Gifford & Co. (4.72%), Renaissance Technologies LLC (3.46%), FMR LLC (1.54%), Bank of New York Mellon Corp (1.43%) and Bank of New York Mellon Corp (1.42%). Company insiders that own ABIOMED stock include Andrew J Greenfield, David M Weber, Dorothy E Puhy, Eric A Md Rose, Martin P Sutter, Michael G Howley, Michael R Minogue, Paul Thomas and William J Bolt. View Institutional Ownership Trends for ABIOMED. Which major investors are selling ABIOMED stock? ABMD stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Winslow Capital Management LLC, Winslow Capital Management LLC, American Century Companies Inc., Bank of New York Mellon Corp, Bank of New York Mellon Corp, Janus Henderson Group PLC and OppenheimerFunds Inc.. Company insiders that have sold ABIOMED company stock in the last year include Andrew J Greenfield, David M Weber, Dorothy E Puhy, Martin P Sutter, Michael G Howley, Michael R Minogue and William J Bolt. View Insider Buying and Selling for ABIOMED. Which major investors are buying ABIOMED stock? ABMD stock was purchased by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, FMR LLC, Carillon Tower Advisers Inc., Sumitomo Mitsui Trust Holdings Inc., Northern Trust Corp, Massachusetts Financial Services Co. MA, Advisors Asset Management Inc. and Schwab Charles Investment Management Inc.. View Insider Buying and Selling for ABIOMED. How do I buy shares of ABIOMED? Shares of ABMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is ABIOMED's stock price today? One share of ABMD stock can currently be purchased for approximately $384.88. How big of a company is ABIOMED? ABIOMED has a market capitalization of $17.27 billion and generates $593.75 million in revenue each year. The medical equipment provider earns $112.17 million in net income (profit) each year or $2.45 on an earnings per share basis. ABIOMED employs 1,143 workers across the globe. What is ABIOMED's official website? The official website for ABIOMED is http://www.abiomed.com. How can I contact ABIOMED? ABIOMED's mailing address is 22 CHERRY HILL DR, DANVERS MA, 01923. The medical equipment provider can be reached via phone at 978-646-1400 or via email at [email protected] MarketBeat Community Rating for ABIOMED (NASDAQ ABMD)Community Ranking: 2.8 out of 5 ( )Outperform Votes: 386 (Vote Outperform)Underperform Votes: 314 (Vote Underperform)Total Votes: 700MarketBeat's community ratings are surveys of what our community members think about ABIOMED and other stocks. Vote "Outperform" if you believe ABMD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ABMD will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 9/24/2018 by MarketBeat.com StaffFeatured Article: How Do Tariffs Affect Trade Balances?